Back Login for AI Analysis

    REGN (STOCKS)

    Regeneron Pharmaceuticals Inc

    $805.970000
    +7.980000 (+1.00%)
    Prev close: $797.990000
    Company Information
    Exchange
    XNAS
    Sector
    Health Technology
    Industry
    Pharmaceuticals: Major
    CEO
    Leonard S. Schleifer
    Asset Type
    stocks
    Website
    Visit
    Fundamentals
    Market Cap
    $87,213.68M
    Employees
    15,207
    P/E (TTM)
    19.72
    P/B (TTM)
    2.60
    Dividend Yield
    45.61%
    Technical Indicators
    SMA 10
    SMA 20
    SMA 50
    EMA 9
    EMA 21
    RSI
    MACD State
    Recent News

    No recent news found for this ticker.

    Financial Statements
    TTM (Jun 2026)
    Revenues $15.53B
    Benefits Costs and Expenses $10.37B
    Costs And Expenses $11.69B
    Nonoperating Income/Loss $1.32B
    Operating Expenses $11.69B
    Selling, General, and Administrative Expenses $2.74B
    Research and Development $6.28B
    Other Operating Expenses $2.67B
    Operating Income/Loss $3.84B
    Income/Loss From Continuing Operations After Tax $4.33B
    Income/Loss From Continuing Operations Before Tax $5.17B
    Income Tax Expense/Benefit $837.30M
    Net Income/Loss $4.33B
    Net Income/Loss Attributable To Noncontrolling Interest $0.00
    Net Income/Loss Attributable To Parent $4.33B
    Net Income/Loss Available To Common Stockholders, Basic $4.33B
    Participating Securities, Distributed And Undistributed Earnings/Loss, Basic $0.00
    Preferred Stock Dividends And Other Adjustments $0.00
    Basic Earnings Per Share $41.91
    Diluted Earnings Per Share $40.44
    Basic Average Shares 206,500,000
    Diluted Average Shares 213,700,000
    Assets $41.73B
    Current Assets $18.45B
    Inventory $3.08B
    Other Current Assets $15.36B
    Noncurrent Assets $23.28B
    Intangible Assets $1.31B
    Other Non-current Assets $21.97B
    Liabilities $10.02B
    Current Liabilities $5.53B
    Accounts Payable $1.16B
    Other Current Liabilities $4.37B
    Noncurrent Liabilities $4.49B
    Equity $31.71B
    Equity Attributable To Noncontrolling Interest $0.00
    Equity Attributable To Parent $31.71B
    Liabilities And Equity $41.73B
    Net Cash Flow From Operating Activities $4.68B
    Net Cash Flow From Operating Activities, Continuing $4.68B
    Net Cash Flow From Investing Activities -$704.20M
    Net Cash Flow From Investing Activities, Continuing -$704.20M
    Net Cash Flow From Financing Activities -$3.52B
    Net Cash Flow From Financing Activities, Continuing -$3.52B
    Exchange Gains/Losses -$1.90M
    Net Cash Flow $450.40M
    Net Cash Flow, Continuing $452.30M
    Comprehensive Income/Loss $4.31B
    Comprehensive Income/Loss Attributable To Noncontrolling Interest $0.00
    Comprehensive Income/Loss Attributable To Parent $4.24B
    Other Comprehensive Income/Loss $3.58B
    Other Comprehensive Income/Loss Attributable To Parent -$88.30M